Print Page     Close Window     
20-F
MESOBLAST LTD filed this Form 20-F on 08/31/2018
Entire Document
 

In the table below we outline the Board’s assessment of performance against the Company KPI’s for the year ended June 30, 2018.

 

Key Objectives

 

Key Objectives Category

 

Key Specified Achievements

 

Weighting

 

 

Rating

 

 

Assessed Performance

 

Execute on specified key objectives within our Tier 1 clinical programs

 

Graft vs Host Disease (GvHD)

 

• Completed enrollment in GvHD Phase 3 Trial

• Primary endpoint successfully achieved

• Successful Day 100 survival

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Chronic Heart Failure (CHF)

 

• Completed enrollment in end stage CHF trial

• Received RMAT status for LVAD patients

• End stage CHF trial results to be presented late 2018

• CHF Ph3 study enrollment continuing as planned

 

55%

 

 

90%

 

 

49.5%

 

 

 

Chronic Lower Back Pain

 

• Phase 3 Study – Enrollment completed

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rheumatoid Arthritis

 

• Reported on positive Phase 2 trial results

 

 

 

 

 

 

 

 

 

 

 

 

Execute on financing and partnering strategy

 

Financing

 

• Funding via successful capital raise A$51 Million

• Executed on a US$75 Million non-dilutive credit facility

• Executed on a US$50 Million financing announced July 2, 2018, including US$40 Million non-dilutive credit facility.

 

35%

 

 

80%

 

 

28.0%

 

 

 

Partnering

 

• Entered into licensing agreement with Takeda

• Entered into a commercial agreement for China for treatment of Heart Disease with China pharmaceutical company -Tasly shortly after completion of financial year

 

 

 

 

 

 

 

 

 

 

 

 

Manufacturing process development

 

 

 

Significant advances achieved in process development for fully scalable manufacture of MPC - bioreactors

 

5%

 

 

70%

 

 

3.5%

 

Organization Structure and Development

 

 

 

• Minimal change in headcount despite continuing increase in activity

• Continued to strengthen employee base with critical new hires

• Significant progress on Board renewal – with the retirement of one NED and the recruitment of 2 new US based NED Directors with outstanding industry experience

 

5%

 

 

80%

 

 

4.0%

 

Assessed Total Company Performance

 

 

 

 

 

100%

 

 

N/A

 

 

85.0%

 

 

102

 



Copyright © 2015 Mesoblast Inc.